195 related articles for article (PubMed ID: 1424280)
1. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE).
Levy E; Ambrus J; Kahl L; Molina H; Tung K; Holers VM
Clin Exp Immunol; 1992 Nov; 90(2):235-44. PubMed ID: 1424280
[TBL] [Abstract][Full Text] [Related]
2. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression.
Masilamani M; von Seydlitz E; Bastmeyer M; Illges H
Immunobiology; 2002 Dec; 206(5):528-36. PubMed ID: 12607728
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus.
Wilson JG; Ratnoff WD; Schur PH; Fearon DT
Arthritis Rheum; 1986 Jun; 29(6):739-47. PubMed ID: 2941021
[TBL] [Abstract][Full Text] [Related]
4. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).
Marquart HV; Svendsen A; Rasmussen JM; Nielsen CH; Junker P; Svehag SE; Leslie RG
Clin Exp Immunol; 1995 Jul; 101(1):60-5. PubMed ID: 7621593
[TBL] [Abstract][Full Text] [Related]
5. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
[TBL] [Abstract][Full Text] [Related]
6. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
7. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
8. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
9. C3d and Epstein-Barr virus (CR2/CD21 ligands) stimulate cells of an HTLV-I line, MT-2.
Kuraya M; Sato T; Fujita T
Microbiol Immunol; 1995; 39(2):145-51. PubMed ID: 7783687
[TBL] [Abstract][Full Text] [Related]
10. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein.
Braun M; Melchers I; Peter HH; Illges H
Int Immunol; 1998 Aug; 10(8):1197-202. PubMed ID: 9723706
[TBL] [Abstract][Full Text] [Related]
11. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
Asokan R; Hua J; Young KA; Gould HJ; Hannan JP; Kraus DM; Szakonyi G; Grundy GJ; Chen XS; Crow MK; Holers VM
J Immunol; 2006 Jul; 177(1):383-94. PubMed ID: 16785534
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
Nemerow GR; Wolfert R; McNaughton ME; Cooper NR
J Virol; 1985 Aug; 55(2):347-51. PubMed ID: 2410629
[TBL] [Abstract][Full Text] [Related]
14. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
[TBL] [Abstract][Full Text] [Related]
16. CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus.
Delibrias CC; Mouhoub A; Fischer E; Kazatchkine MD
Eur J Immunol; 1994 Nov; 24(11):2784-8. PubMed ID: 7957570
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV-infected persons.
June RA; Landay AL; Stefanik K; Lint TF; Spear GT
Immunology; 1992 Jan; 75(1):59-65. PubMed ID: 1371493
[TBL] [Abstract][Full Text] [Related]
18. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice.
Takahashi K; Kozono Y; Waldschmidt TJ; Berthiaume D; Quigg RJ; Baron A; Holers VM
J Immunol; 1997 Aug; 159(3):1557-69. PubMed ID: 9233655
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
20. B cell activation leads to shedding of complement receptor type II (CR2/CD21).
Masilamani M; Kassahn D; Mikkat S; Glocker MO; Illges H
Eur J Immunol; 2003 Sep; 33(9):2391-7. PubMed ID: 12938215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
